Lastly, to address whether the immune-inflammatory perturbations we observed in melanoma patients at baseline are influenced by currently available nivolumab treatment, we measured the frequency distribution of circulating CD4+CD26high levels in a sub-cohort of 33 cases. Here, CD4 is linked to melanoma.